Moneycontrol PRO
Black Friday Sale
Black Friday Sale
HomeNewsBusinessLesser hospitalisations a ‘huge relief’, we need to brace ourselves for variants, Omicron not the last one, says Kiran Mazumdar-Shaw

Lesser hospitalisations a ‘huge relief’, we need to brace ourselves for variants, Omicron not the last one, says Kiran Mazumdar-Shaw

The Biocon chief added that added that hospitals are “more prepared this time” and Delta is also not as big a worry as we now know how to deal with it

January 03, 2022 / 14:42 IST
Biocon Chairperson Kiran Mazumdar-Shaw

Lower number of hospitalisations and occupation of ICU beds amid an unprecedented surge in COVID-19 infections is a “huge relief”, Biocon chairperson Kiran Mazumdar-Shaw told CNBC-TV18 in an exclusive interview on January 3.

On the Omicron variant, Mazumdar-Shaw said the variant is “surging fast, but also descends quickly”, adding: “We need to brace ourselves for many variants, Omicron is not the last.”

She added that hospitals are “more prepared this time and we are veering towards an endemic situation” and that Delta “should also not be a huge worry” as we now know how to deal with it.

Her statements came as COVID-19 cases are rising and as the Centre launched vaccinations for 15-17 year-olds in the country.

“It is important that we need to look at vaccinating children sooner or later. So we need to speed up pediatric trials as soon as possible and start taking rolling reviews on the vaccination trials for children below the age of 15,” Mazumdar-Shaw added.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

She also noted that the private can help better deploy the new vaccines that have been approved, adding that they should also be given access to genome sequencing.

“I also believe that we need to ramp up our genomic sequencing, which I think needs to be opened up to the private sector as well,” she said.

Moneycontrol News
first published: Jan 3, 2022 02:14 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347